Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?

被引:3
|
作者
Turkdogan, Sena [1 ]
Pusztaszeri, Marc [2 ]
Forest, Veronique-Isabelle [1 ]
Hier, Michael P. [1 ]
Payne, Richard J. [1 ]
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Dept Otolaryngol Head & Neck Surg, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada
关键词
thyroid cancer; thyroid nodule; Bethesda; molecular testing; FINE-NEEDLE ASPIRATIONS; UNDETERMINED SIGNIFICANCE; EXTRATHYROIDAL EXTENSION; SOLID VARIANT; CARCINOMA; CATEGORY; ATYPIA; SYSTEM; SUBCLASSIFICATION; CYTOLOGY;
D O I
10.3390/cancers12092563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The Bethesda classification system is a widespread tool used in the initial screening test for thyroid nodules. The system classifies the biopsy of the nodule into 6 categories, each with its associated malignancy risk and recommendations for management. Nodules classified as Bethesda III and IV are considered intermediate risk, and although Bethesda III nodules are more likely to be benign than Bethesda IV, our hypothesis is that out of those that are malignant, a subset may be more aggressive given their diverse cellular features. In this study we looked at 628 individuals who underwent surgery with a Bethesda III or IV nodule and compared the number of aggressive features found in those with confirmed malignancy. We discovered that Bethesda III nodules that were found to be malignant were more likely to have aggressive features, such as aggressive sub-types of thyroid cancer, spread of cancer beyond the thyroid capsule, and spread of cancer to the lymph nodes. Our results suggest that Bethesda III thyroid nodules may not as indolent as they seem, and these findings may affect management decisions in individuals with indeterminate thyroid nodules. The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [31] TSH Level and Risk of Malignancy in Patients with Bethesda Category IV Thyroid Nodules
    Carolina Fernández-Trujillo
    Julio Pérez-Zaballos
    Carlos A. Rodríguez-Pérez
    Yaiza López-Plasencia
    Dunia Marrero-Arencibia
    Juan J. Cabrera-Galván
    Mauro Boronat
    Hormones and Cancer, 2020, 11 : 200 - 204
  • [32] Diagnostic thyroid lobectomy versus active surveillance in the management of Bethesda class III thyroid nodules
    Goh, Xueying
    Ting, Yohanes
    Nga, Min En
    Lim, Ling Choo
    Lim, Chwee Ming
    ASIAN JOURNAL OF SURGERY, 2020, 43 (11) : 1108 - 1109
  • [33] Thyroid imaging reporting and data system in assessment of cytological Bethesda Category III thyroid nodules
    Mao, Feng
    Xu, Hui-Xiong
    Zhao, Chong-Ke
    Bo, Xiao-Wan
    Li, Xiao-Long
    Li, Dan-Dan
    Liu, Bo-Ji
    Zhang, Yi-Feng
    Xu, Jun-Mei
    Qu, Shen
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2017, 65 (02) : 163 - 173
  • [34] Value of Thyroid Imaging Reporting and Data System in Initial Bethesda Category III Thyroid Nodules
    Yan, Caoxin
    Luo, Zhiyan
    Lin, Zimei
    Xu, Shouxing
    Luo, Yunkai
    Chen, Jian
    SCIENTIFIC PROGRAMMING, 2021, 2021
  • [35] Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region
    Loderer, Tommaso
    Bonati, Elena
    Donato, Valentina
    Viani, Lorenzo
    Cozzani, Federico
    Del Rio, Paolo
    GLAND SURGERY, 2023, 12 (07) : 884 - 893
  • [36] TSH Level and Risk of Malignancy in Patients with Bethesda Category IV Thyroid Nodules
    Fernandez-Trujillo, Carolina
    Perez-Zaballos, Julio
    Rodriguez-Perez, Carlos A.
    Lopez-Plasencia, Yaiza
    Marrero-Arencibia, Dunia
    Cabrera-Galvan, Juan J.
    Boronat, Mauro
    HORMONES & CANCER, 2020, 11 (3-4): : 200 - 204
  • [37] Preliminary Report of Active Surveillance as a Conservative Strategy for Bethesda IV Thyroid Nodules
    Garcia-Lozano, Carlos Andres
    Sanabria, Alvaro
    THYROID, 2023, 33 (01) : 126 - 128
  • [38] Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
    Kiernan, Colleen M.
    Solorzano, Carmen C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (01) : 77 - 82
  • [39] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)
    Ho, Allen S.
    Sarti, Evan E.
    Jain, Kunal S.
    Wang, Hangjun
    Nixon, Iain J.
    Shaha, Ashok R.
    Shah, Jatin P.
    Kraus, Dennis H.
    Ghossein, Ronald
    Fish, Stephanie A.
    Wong, Richard J.
    Lin, Oscar
    Morris, Luc G. T.
    THYROID, 2014, 24 (05) : 832 - 839
  • [40] Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
    Kuta, Victoria
    Forner, David
    Azzi, Jason
    Curry, Dennis
    Noel, Christopher W.
    Munroe, Kelti
    Bullock, Martin
    McDonald, Ted
    Taylor, S. Mark
    Rigby, Matthew H.
    Trites, Jonathan
    Johnson-Obaseki, Stephanie
    Corsten, Martin J.
    OTO OPEN, 2021, 5 (02)